New pharmacotherapies for the erythropoietic protoporphyrias: an analysis of trial protocols from a patient perspective
Cornelia Dechant, Sebastian Wäscher, Francesca Granata, Nicole Gusset, Mårten Pettersson, Mehmet Hakan Aksözen, Marc Höglinger, Rocco Falchetto, Jasmin Barman-Aksözen · 2025
Read New pharmacotherapies for the erythropoietic protoporphyrias: an analysis of trial protocols from a patient perspective by Cornelia Dechant, Sebastian Wäscher, Francesca Granata, Nicole Gusset, Mårten Pettersson, Mehmet Hakan Aksözen, Marc Höglinger, Rocco Falchetto, Jasmin Barman-Aksözen (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12751534.txt.
Description
Cornelia Dechant and co-authors analyze new drug trials for a rare blood disorder from the patient's view in a 2025 paper. The protoporphyrias cause painful skin reactions to visible light. Only one drug is approved, and it prevents reactions and lifts life quality for many patients.
Several new candidates entered trials in recent years. The team identified those in current trials and compared their designs, asking how safety and benefit will be judged against the existing drug. Trial burdens and endpoints matter greatly in ultra-rare disease, where each patient counts. The analysis gives patient advocates concrete points to press with sponsors.
Catalog record
| CREATOR | Cornelia Dechant, Sebastian Wäscher, Francesca Granata, Nicole Gusset, Mårten Pettersson, Mehmet Hakan Aksözen, Marc Höglinger, Rocco Falchetto, Jasmin Barman-Aksözen |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 61 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |